Gilder Gagnon Howe & CO LLC Taysha Gene Therapies, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$11.43 - $19.2 $429,516 - $721,497	-37,578 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$15.82 - $21.57 $980 - $1,337	-62 Reduced 0.16%	37,578 $700,000
Q2 2021 Aug 16, 2021	SELL	$19.29 - $26.38 $3,549 - $4,853	-184 Reduced 0.49%	37,640 $798,000
Q1 2021 May 17, 2021	SELL	$20.3 - $31.75 $64,533 - $100,933	-3,179 Reduced 7.75%	37,824 $768,000
Q4 2020 Feb 16, 2021	SELL	$19.14 - $28.13 $46,069 - $67,708	-2,407 Reduced 5.54%	41,003 $1.09 Million
Q3 2020 Nov 16, 2020	BUY	$22.4 - $24.47 $972,383 - $1.06 Million	43,410 New	43,410 $972,000

119

136M

25.9K

24K

Ticker TSHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,359,500
Market Cap $97.2M
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.